CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Increasing preference for non-invasive procedures
4.1.2. Technological advancements in breast cancer liquid biopsy
4.1.3. Rising emphasis on personalised medicine and a high burden of cancer
4.1.4. Availability of funding for liquid biopsy R&D
4.2. Market Restraints & Challenges
4.2.1. Unclear regulatory and reimbursement scenario
4.2.2. Low sensitivity and specificity of breast cancer
CHAPTER 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET – BY
CIRCULATING BIOMARKERS
5.1. Cell-free DNA
5.2. Circulating tumour cells
5.3. Extracellular Vesicles
5.4. Others
CHAPTER 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET – BY END
USER
6.1. Reference Laboratories
6.2. Hospitals & Physician Laboratories
6.3. Others
CHAPTER 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET - BY
GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.2.4. Costa Rica
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Chile
7.3.4. Columbia
7.3.5. Others
7.4. Europe
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Netherlands
7.4.8. Switzerland
7.4.9. Poland
7.4.10. Others
7.5. APAC
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. South Korea
7.5.5. Australia & New Zealand
7.5.6. Malaysia
7.5.7. Singapore
7.5.8. Others
7.6. Middle East & Africa
7.6.1. UAE
7.6.2. Saudi Arabia
7.6.3. Iran
7.6.4. Iraq
7.6.5. Qatar
7.6.6. South Africa
7.6.7. Algeria
7.6.8. Morocco
7.6.9. Nigeria
7.6.10. Egypt
7.6.11. Others
CHAPTER 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET - COMPANY
PROFILES
8.1. QIAGEN N.V.
8.2. Roche Diagnostics
8.3. Illumina, Inc.
8.4. Bio-Rad Laboratories
8.5. Myriad Genetics
8.6. Menarini Silicon Biosystems
8.7. Cynvenio Biosystems, Inc.
8.8. Genomic Health, Inc.
8.9. Thermo Fisher Scientific Inc.
8.10. Fluxion Biosciences, Inc.
8.11. Biodesix, Inc.
8.12. Guardant Health, Inc.
8.13. Isogen Life Science B.V.
CHAPTER 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET -
COMPETITIVE LANDSCAPE
9.1. Market Share Analysis
9.2. Strategies adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 10. MARKET INSIGHTS
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
CHAPTER 11. APPENDIX
11.1. List of Tables
11.2. List of Figures
